Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baselga, J.
Right arrow Articles by Norton, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baselga, J.
Right arrow Articles by Norton, L.

Journal of Clinical Oncology, Vol 14, 737-744, Copyright © 1996 by American Society of Clinical Oncology

ARTICLES

Phase II study of weekly intravenous recombinant humanized anti- p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

J Baselga, D Tripathy, J Mendelsohn, S Baughman, CC Benz, L Dantis, NT Sklarin, AD Seidman, CA Hudis, J Moore, PP Rosen, T Twaddell, IC Henderson and L Norton
Department of Medicine, Services of Breast and Gynecological Cancer Medicine and Clinical Immunology, Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

PURPOSE: Breast cancer frequently overexpresses the product of the HER2 proto-oncogene, a 185-kd growth factor receptor (p185HER2). The recombinant humanized monoclonal antibody (rhuMAb) HER2 has high affinity for p185HER2 and inhibits the growth of breast cancer cells that overexpress HER2. We evaluated the efficacy and toxicity of weekly intravenous administration of rhuMAb HER2 in patients with HER2- overexpressing metastatic breast cancer. PATIENTS AND METHODS: We treated 46 patients with metastatic breast carcinomas that overexpressed HER2. Patients received a loading dose of 250 mg of intravenous rhuMAb HER2, then 10 weekly doses of 100 mg each. Patients with no disease progression at the completion of this treatment period were offered a maintenance phase of 100 mg/wk. RESULTS: Study patients had extensive metastatic disease, and most had received extensive prior anticancer therapy. Adequate pharmacokinetic levels of rhuMAb HER2 were obtained in 90% of the patients. Toxicity was minimal and no antibodies against rhuMAb HER2 were detected in any patients. Objective responses were seen in five of 43 assessable patients, and included one complete remission and four partial remissions (overall response rate, 11.6%; 95% confidence interval, 4.36 to 25.9). Responses were observed in liver, mediastinum, lymph nodes, and chest wall lesions. Minor responses, seen in two patients, and stable disease, which occurred in 14 patients, lasted for a median of 5.1 months. CONCLUSION: rhuMAb HER2 is well tolerated and clinically active in patients with HER2- overexpressing metastatic breast cancers that had received extensive prior therapy. This is evidence that targeting growth factor receptors can cause regression of human cancer and justifies further evaluation of this agent.


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
I. N. Fleming, M. Hogben, S. Frame, S. J. McClue, and S. R. Green
Synergistic Inhibition of ErbB Signaling by Combined Treatment with Seliciclib and ErbB-Targeting Agents
Clin. Cancer Res., July 1, 2008; 14(13): 4326 - 4335.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
K. Bullock and K. Blackwell
Clinical Efficacy of Taxane-Trastuzumab Combination Regimens for HER-2-Positive Metastatic Breast Cancer
Oncologist, May 1, 2008; 13(5): 515 - 525.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. M. Park, M. Terabe, J. C. Steel, G. Forni, Y. Sakai, J. C. Morris, and J. A. Berzofsky
Therapy of Advanced Established Murine Breast Cancer with a Recombinant Adenoviral ErbB-2/neu Vaccine
Cancer Res., March 15, 2008; 68(6): 1979 - 1987.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Harris, H. Fritsche, R. Mennel, L. Norton, P. Ravdin, S. Taube, M. R. Somerfield, D. F. Hayes, and R. C. Bast Jr
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
J. Clin. Oncol., November 20, 2007; 25(33): 5287 - 5312.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T.-H. Huang, K. R. Chintalacharuvu, and S. L. Morrison
Targeting IFN-{alpha} to B Cell Lymphoma by a Tumor-Specific Antibody Elicits Potent Antitumor Activities
J. Immunol., November 15, 2007; 179(10): 6881 - 6888.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. F. Eddy, S. E. Kane, and G. E. Sonenshein
Trastuzumab-Resistant HER2-Driven Breast Cancer Cells Are Sensitive to Epigallocatechin-3 Gallate
Cancer Res., October 1, 2007; 67(19): 9018 - 9023.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
C. A. Hudis
Trastuzumab -- Mechanism of Action and Use in Clinical Practice
N. Engl. J. Med., July 5, 2007; 357(1): 39 - 51.
[Full Text] [PDF]

Home page
 The OncologistHome page
S. Gori, S. Rimondini, V. De Angelis, M. Colozza, G. Bisagni, G. Moretti, A. Sidoni, C. Basurto, C. Aristei, P. Anastasi, et al.
Central Nervous System Metastases in HER-2 Positive Metastatic Breast Cancer Patients Treated with Trastuzumab: Incidence, Survival, and Risk Factors
Oncologist, July 1, 2007; 12(7): 766 - 773.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. Scaltriti, F. Rojo, A. Ocana, J. Anido, M. Guzman, J. Cortes, S. Di Cosimo, X. Matias-Guiu, S. Ramon y Cajal, J. Arribas, et al.
Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer
J Natl Cancer Inst, April 18, 2007; 99(8): 628 - 638.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. M. Scott, F.-T. Lee, N. Tebbutt, R. Herbertson, S. S. Gill, Z. Liu, E. Skrinos, C. Murone, T. H. Saunder, B. Chappell, et al.
A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors
PNAS, March 6, 2007; 104(10): 4071 - 4076.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Huang, K. Reeves, X. Han, C. Fairchild, S. Platero, T. W. Wong, F. Lee, P. Shaw, and E. Clark
Identification of Candidate Molecular Markers Predicting Sensitivity in Solid Tumors to Dasatinib: Rationale for Patient Selection
Cancer Res., March 1, 2007; 67(5): 2226 - 2238.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Jimeno, B. Rubio-Viqueira, M. L. Amador, V. Grunwald, A. Maitra, C. Iacobuzio-Donahue, and M. Hidalgo
Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer
Mol. Cancer Ther., March 1, 2007; 6(3): 1079 - 1088.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. M. Diehl, E. T. Keller, and K. M. Woods Ignatoski
Why should we still care about oncogenes?
Mol. Cancer Ther., February 1, 2007; 6(2): 418 - 427.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. Nahta, L. X.H. Yuan, Y. Du, and F. J. Esteva
Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling
Mol. Cancer Ther., February 1, 2007; 6(2): 667 - 674.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. R. James, J. E. Quinn, P. B. Mullan, P. G. Johnston, and D. P. Harkin
BRCA1, a Potential Predictive Biomarker in the Treatment of Breast Cancer
Oncologist, February 1, 2007; 12(2): 142 - 150.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. R. Luo, Z. Yang, A. Camuso, R. Smykla, K. McGlinchey, K. Fager, C. Flefleh, S. Castaneda, I. Inigo, D. Kan, et al.
Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure
Clin. Cancer Res., December 1, 2006; 12(23): 7180 - 7186.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Meric-Bernstam and M.-C. Hung
Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy.
Clin. Cancer Res., November 1, 2006; 12(21): 6326 - 6330.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. F. Hayes and M. H. Picard
Heart of Darkness: The Downside of Trastuzumab
J. Clin. Oncol., September 1, 2006; 24(25): 4056 - 4058.
[Full Text] [PDF]

Home page
 JCOHome page
J. A. Menendez, I. Mehmi, and R. Lupu
Trastuzumab in Combination With Heregulin-Activated Her-2 (erbB-2) Triggers a Receptor-Enhanced Chemosensitivity Effect in the Absence of Her-2 Overexpression
J. Clin. Oncol., August 10, 2006; 24(23): 3735 - 3746.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
E. A. Mittendorf, C. E. Storrer, C. D. Shriver, S. Ponniah, and G. E. Peoples
Investigating the Combination of Trastuzumab and HER2/neu Peptide Vaccines for the Treatment of Breast Cancer
Ann. Surg. Oncol., August 1, 2006; 13(8): 1085 - 1098.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. N. Krag, G. S. Shukla, G.-P. Shen, S. Pero, T. Ashikaga, S. Fuller, D. L. Weaver, S. Burdette-Radoux, and C. Thomas
Selection of Tumor-binding Ligands in Cancer Patients with Phage Display Libraries.
Cancer Res., August 1, 2006; 66(15): 7724 - 7733.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Jerome, N. Alami, S. Belanger, V. Page, Q. Yu, J. Paterson, L. Shiry, M. Pegram, and B. Leyland-Jones
Recombinant Human Insulin-like Growth Factor Binding Protein 3 Inhibits Growth of Human Epidermal Growth Factor Receptor-2-Overexpressing Breast Tumors and Potentiates Herceptin Activity In vivo.
Cancer Res., July 15, 2006; 66(14): 7245 - 7252.
[Abstract] [Full Text] [PDF]

Home page
 Protein Eng Des SelHome page
A. Nguyen, A. E. Reyes II, M. Zhang, P. McDonald, W. L. T. Wong, L. A. Damico, and M. S. Dennis
The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin
Protein Eng. Des. Sel., July 1, 2006; 19(7): 291 - 297.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
G. Helguera, J. A. Rodriguez, and M. L. Penichet
Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2/neu expressing tumors.
Mol. Cancer Ther., April 1, 2006; 5(4): 1029 - 1040.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
P Kauraniemi and A Kallioniemi
Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer.
Endocr. Relat. Cancer, March 1, 2006; 13(1): 39 - 49.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
J. B Engel, A. V Schally, G. Halmos, B. Baker, A. Nagy, and G. Keller
Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins
Endocr. Relat. Cancer, December 1, 2005; 12(4): 999 - 1009.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Nahta, L. X.H. Yuan, B. Zhang, R. Kobayashi, and F. J. Esteva
Insulin-like Growth Factor-I Receptor/Human Epidermal Growth Factor Receptor 2 Heterodimerization Contributes to Trastuzumab Resistance of Breast Cancer Cells
Cancer Res., December 1, 2005; 65(23): 11118 - 11128.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. P. Delord, C. Allal, M. Canal, E. Mery, P. Rochaix, I. Hennebelle, A. Pradines, E. Chatelut, R. Bugat, S. Guichard, et al.
Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma
Ann. Onc., December 1, 2005; 16(12): 1889 - 1897.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. J. Piccart-Gebhart, M. Procter, B. Leyland-Jones, A. Goldhirsch, M. Untch, I. Smith, L. Gianni, J. Baselga, R. Bell, C. Jackisch, et al.
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
N. Engl. J. Med., October 20, 2005; 353(16): 1659 - 1672.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
W. P. Tew, D. P. Kelsen, and D. H. Ilson
Targeted Therapies for Esophageal Cancer
Oncologist, September 1, 2005; 10(8): 590 - 601.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Baselga, J. Albanell, A. Ruiz, A. Lluch, P. Gascon, V. Guillem, S. Gonzalez, S. Sauleda, I. Marimon, J. M. Tabernero, et al.
Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer
J. Clin. Oncol., August 10, 2005; 23(23): 5323 - 5333.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. A. Adjei and M. Hidalgo
Intracellular Signal Transduction Pathway Proteins As Targets for Cancer Therapy
J. Clin. Oncol., August 10, 2005; 23(23): 5386 - 5403.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. J. Cohen, R. B. Cohen, and N. J. Meropol
Targeting Signal Transduction Pathways in Colorectal Cancer--More Than Skin Deep
J. Clin. Oncol., August 10, 2005; 23(23): 5374 - 5385.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
C. T. Viehl, M. Becker-Hapak, J. S. Lewis, Y. Tanaka, U. K. Liyanage, D. C. Linehan, T. J. Eberlein, and P. S. Goedegebuure
A Tat Fusion Protein-Based Tumor Vaccine for Breast Cancer
Ann. Surg. Oncol., July 1, 2005; 12(7): 517 - 525.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. G. Dressler, D. A. Berry, G. Broadwater, D. Cowan, K. Cox, S. Griffin, A. Miller, J. Tse, D. Novotny, D. L. Persons, et al.
Comparison of HER2 Status by Fluorescence in Situ Hybridization and Immunohistochemistry to Predict Benefit From Dose Escalation of Adjuvant Doxorubicin-Based Therapy in Node-Positive Breast Cancer Patients
J. Clin. Oncol., July 1, 2005; 23(19): 4287 - 4297.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. M. Scott, F.-T. Lee, R. Jones, W. Hopkins, D. MacGregor, J. S. Cebon, A. Hannah, G. Chong, P. U, A. Papenfuss, et al.
A Phase I Trial of Humanized Monoclonal Antibody A33 in Patients with Colorectal Carcinoma: Biodistribution, Pharmacokinetics, and Quantitative Tumor Uptake
Clin. Cancer Res., July 1, 2005; 11(13): 4810 - 4817.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Mimura, K. Kono, M. Hanawa, M. Kanzaki, A. Nakao, A. Ooi, and H. Fujii
Trastuzumab-Mediated Antibody-Dependent Cellular Cytotoxicity against Esophageal Squamous Cell Carcinoma
Clin. Cancer Res., July 1, 2005; 11(13): 4898 - 4904.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. U. Buzdar, N. K. Ibrahim, D. Francis, D. J. Booser, E. S. Thomas, R. L. Theriault, L. Pusztai, M. C. Green, B. K. Arun, S. H. Giordano, et al.
Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer
J. Clin. Oncol., June 1, 2005; 23(16): 3676 - 3685.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. B. Michel, P. M. Andrews, M. E. Castillo, and M. J. Mattes
In vitro cytotoxicity of carcinoma cells with 111In-labeled antibodies to HER-2
Mol. Cancer Ther., June 1, 2005; 4(6): 927 - 937.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
H.-M. Cho, J. D. Rosenblatt, Y.-S. Kang, M. L. Iruela-Arispe, S. L. Morrison, M. L. Penichet, Y.-G. Kwon, T.-W. Kim, K. A. Webster, H. Nechustan, et al.
Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein
Mol. Cancer Ther., June 1, 2005; 4(6): 956 - 967.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Baselga, X. Carbonell, N.-J. Castaneda-Soto, M. Clemens, M. Green, V. Harvey, S. Morales, C. Barton, and P. Ghahramani
Phase II Study of Efficacy, Safety, and Pharmacokinetics of Trastuzumab Monotherapy Administered on a 3-Weekly Schedule
J. Clin. Oncol., April 1, 2005; 23(10): 2162 - 2171.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
B. S. Kochupurakkal, D. Harari, A. Di-Segni, G. Maik-Rachline, L. Lyass, G. Gur, G. Kerber, A. Citri, S. Lavi, R. Eilam, et al.
Epigen, the Last Ligand of ErbB Receptors, Reveals Intricate Relationships between Affinity and Mitogenicity
J. Biol. Chem., March 4, 2005; 280(9): 8503 - 8512.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. A. Menendez, L. Vellon, R. Colomer, and R. Lupu
Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (HerceptinTM) in breast cancer cells with Her-2/neu oncogene amplification
Ann. Onc., March 1, 2005; 16(3): 359 - 371.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Nagy, E. Friedlander, M. Tanner, A. I. Kapanen, K. L. Carraway, J. Isola, and T. M. Jovin
Decreased Accessibility and Lack of Activation of ErbB2 in JIMT-1, a Herceptin-Resistant, MUC4-Expressing Breast Cancer Cell Line
Cancer Res., January 15, 2005; 65(2): 473 - 482.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
P. Carter, L. Smith, and M. Ryan
Identification and validation of cell surface antigens for antibody targeting in oncology
Endocr. Relat. Cancer, December 1, 2004; 11(4): 659 - 687.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Christiansen and A. K. Rajasekaran
Biological impediments to monoclonal antibody-based cancer immunotherapy
Mol. Cancer Ther., November 1, 2004; 3(11): 1493 - 1501.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Nieto, J. J. Vredenburgh, E. J. Shpall, S. I. Bearman, P. A. McSweeney, N. Chao, D. Rizzieri, C. Gasparetto, S. Matthes, A. E. Baron, et al.
Phase II Feasibility and Pharmacokinetic Study of Concurrent Administration of Trastuzumab and High-Dose Chemotherapy in Advanced HER2+ Breast Cancer
Clin. Cancer Res., November 1, 2004; 10(21): 7136 - 7143.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Cianfrocca and L. J. Goldstein
Prognostic and Predictive Factors in Early-Stage Breast Cancer
Oncologist, November 1, 2004; 9(6): 606 - 616.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. M. Slomovitz, R. R. Broaddus, T. W. Burke, N. Sneige, P. T. Soliman, W. Wu, C. C. Sun, M. F. Munsell, D. M. Gershenson, and K. H. Lu
Her-2/neu Overexpression and Amplification in Uterine Papillary Serous Carcinoma
J. Clin. Oncol., August 1, 2004; 22(15): 3126 - 3132.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. Osborne, P. Wilson, and D. Tripathy
Oncogenes and Tumor Suppressor Genes in Breast Cancer: Potential Diagnostic and Therapeutic Applications
Oncologist, July 1, 2004; 9(4): 361 - 377.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. T. Dang, A. J. Dannenberg, K. Subbaramaiah, M. N. Dickler, M. M. Moasser, A. D. Seidman, G. M. D'Andrea, M. Theodoulou, K. S. Panageas, L. Norton, et al.
Phase II Study of Celecoxib and Trastuzumab in Metastatic Breast Cancer Patients Who Have Progressed after Prior Trastuzumab-Based Treatments
Clin. Cancer Res., June 15, 2004; 10(12): 4062 - 4067.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Nahta, T. Takahashi, N. T. Ueno, M.-C. Hung, and F. J. Esteva
P27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells
Cancer Res., June 1, 2004; 64(11): 3981 - 3986.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. W. Park, R. S. Kerbel, G. J. Kelloff, J. C. Barrett, B. A. Chabner, D. R. Parkinson, J. Peck, R. W. Ruddon, C. C. Sigman, and D. J. Slamon
Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development
Clin. Cancer Res., June 1, 2004; 10(11): 3885 - 3896.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. J. S. Rustin, R. C. Bast Jr., G. J. Kelloff, J. C. Barrett, S. K. Carter, P. D. Nisen, C. C. Sigman, D. R. Parkinson, and R. W. Ruddon
Use of CA-125 in Clinical Trial Evaluation of New Therapeutic Drugs for Ovarian Cancer
Clin. Cancer Res., June 1, 2004; 10(11): 3919 - 3926.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. J. Kelloff, D. S. Coffey, B. A. Chabner, A. P. Dicker, K. Z. Guyton, P. D. Nisen, H. R. Soule, and A. V. D'Amico
Prostate-Specific Antigen Doubling Time as a Surrogate Marker for Evaluation of Oncologic Drugs to Treat Prostate Cancer
Clin. Cancer Res., June 1, 2004; 10(11): 3927 - 3933.
[Full Text] [PDF]